[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Chinese University of Hong Kong\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":618},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,381,0,25,[9,41,72,93,116,144,170,200,225,245,265,285,308,326,355,383,401,419,447,472,496,527,548,569,599],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100053872","phase-2-js207-a-bispecific-antibody-against-pd1-vegf-in-nasopharyngeal-carcinoma-100053872",false,"NCT07690787","JS207 a Bispecific Antibody Against PD1-VEGF in Nasopharyngeal Carcinoma","Phase I-II Study of JS207 a Bispecific Antibody Against PD1-VEGF in the Treatment of Recurrent\u002FMetastatic Nasopharyngeal Carcinoma","Inclusion Criteria:\n\n* Known histologically confirmed diagnosis of nasopharyngeal carcinoma\n* Measurable disease according to RECIST ver 1.1.\n* Age 18 or above and younger than 80 years old; ECOG performance 0 or 1.\n* Adequate bone marrow, renal and hepatic reserve, and clotting profile:\n\n  1. Absolute neutrophil count ≥ 1.5 × 10\\^9 \u002FL; Platelets ≥ 90×10\\^9 \u002FL; Hemoglobin \\> 9 g\u002FdL.\n  2. Serum creatinine ≤ 1.5 × ULN or calculated creatinine clearance ≥ 50 mL\u002Fmin (Cockcroft-Gault formula).\n  3. Total bilirubin ≤ 1.5 × ULN, AST and ALT ≤ 2.5 × ULN for patients without liver metastases.\n  4. Total bilirubin ≤ 3.0 × ULN, AST and ALT ≤ 5.0 × ULN for patients with liver metastases.\n  5. INR and APTT ≤ 1.5 × ULN\n  6. Electrocardiography (ECG): Friderica-corrected QT interval (QTcF): ≤470 (females) or ≤450 (males) milliseconds without a history of congenital long QT syndrome\n* Urine strip test (multistix or dipstick) showing protein ≤2+; if urine protein characterization \\>2+, 24 h urine protein quantification is required; if 24 h urine protein quantification \\\u003C1 g, it is acceptable;\n* Female or male subjects of childbearing potential must agree to have no plans for childbearing and to voluntarily use highly effective contraception with their partner for the duration of the study for up to 6 months after the end of the last dose, and female subjects of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to the first dose of study medication.\n* Prior treatment with PD1\u002FPDL1 inhibitor as part of neoadjuvant treatment or concurrently with radical radiotherapy with curative intent is allowed as long as there is an interval of 6 or more months since administration of the last dose of PD1 inhibitor and more than 12 months since radical radiotherapy +\u002F- concomitant chemotherapy.\n* Prior treatment with PD1\u002FPDL1 inhibitor for the first-line treatment of R\u002FN NPC is allowed, as long as there is an interval of 6 or more months since administration of the last dose of PD1\u002FPDL1 inhibitor.\n\nExclusion Criteria:\n\n* Prior radical RT to the primary NPC within 12 months\n* Known history of nasopharyngeal necrosis\n* Presence of locoregional tumor recurrence or distant metastatic disease associated with invasion of major vascular structure(s) on imaging which may increase the risk of serious bleeding. This may include (but not limited to) regional neck recurrence invading major vascular structures or ;\n* Presence of central lung lesions involving major blood vessels;\n* History of clinically significant bleeding defined as Grade 2 epistaxis or Grade 3 bleeding at other sites occurring within 4 weeks prior to the first dose of study drug.\n* Prior therapy with anti-vascular agents in any clinical setting, including anti-VEGF antibodies or tyrosine kinase-inhibitors targeting VEGFR.\n* Uncontrolled hypertension defined as consistently more than 150\u002F100 mmHg despite adequate medical therapy or history of hypertensive crisis or hypertensive encephalopathy;\n* Known history of hypersensitivity to any components of the study drug formulation, or other monoclonal antibodies\n* Prior therapy with anti-vascular agents in any clinical setting, including anti-VEGF antibodies, tyrosine kinase-inhibitor agent targeting at VEGFR.\n* Patients who are on anticoagulants.\n* Presence of significant bleeding tendencies or history of severe coagulation disorders;\n* Known history of nasopharyngeal necrosis\n* Patients with arteriovenous thrombosis events, such as cerebrovascular accident (including temporary ischemic attack, cerebral hemorrhage, cerebral infarction), deep venous thrombosis (except venous thrombosis caused by intravenous catheterization due to early chemotherapy) and pulmonary embolism, occurred within 6 months.\n* Patients with urine strip test (multi-stix or dipstick) indicating urine protein \\> 2+ will need a 24-hour urine protein collection. They are excluded if the 24-hour urine protein is \\>1.0g.\n* Presence of symptomatic central nervous system metastases that require use of steroids of dose \\> prednisolone 10mg daily or equivalent.\n* Presence of active autoimmune disease not related to prior use of PD1\u002FPDL1 inhibitor, that require systemic therapy (e.g., use of corticosteroids or immunosuppressive medications) within 2 years prior to the first dose, including, but not limited to: systemic lupus erythematosus, multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease or vasculitis. However, enrollment is allowed for patients with hypothyroidism, adrenal gland, hypophysis, or pituitary gland dysfunction, or type 1 diabetes mellitus that can be controlled with hormone replacement therapy only or vitiligo or psoriasis not requiring systemic therapy;\n* History of interstitial lung disease or prior history of pneumonitis that required immunosuppressive therapy including steroids; patients with a history of Grade 1 radiation pneumonitis are eligible;\n* Gastrointestinal (GI) perforation of or fistula involving internal organs or intra-abdominal or thoracic abscesses within 6 months prior to the first dose of study drug;\n* Presence of severe, unhealed or open wounds, active ulcers or untreated fractures;\n* Presence of significant bleeding tendencies or history of severe coagulation disorders;\n* Presence of poorly controlled hypertension (systolic blood pressure ≥150 mmHg and\u002For diastolic blood pressure \\>100 mmHg) on more than 3 separate readings obtained on different days at the clinic, or history of hypertensive crisis or hypertensive encephalopathy;\n* History of immunodeficiency, including a positive test for human immunodeficiency virus (HIV), or a known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation;\n* Have serious cardiovascular disease including, but not limited to, myocardial infarction, severe\u002Funstable angina pectoris, myocarditis, pericarditis, congestive heart failure (NYHA cardiac function class ≥ grade 2), clinically significant supraventricular or ventricular arrhythmia requiring pharmacologic intervention, aortic aneurysm requiring surgical repair, any arterial thrombotic\u002Fembolic event, grade 3 and above (Generic for adverse events, Terminology Criteria \\[CTCAE 65.0) venous thrombotic\u002Fembolic event, transient ischemic attack, cerebrovascular accident;\n* Active infections that require intravenous anti-infective agents within 28 days prior to the first study dose. Known active tuberculosis, uncontrolled hepatitis B (hepatitis B surface antigen \\[HBsAg\\] positive and HBV DNA above the lower limit of detection of the study center), hepatitis C (HCV Ab positive and HCV RNA above the lower limit of detection of the study center);\n* History of another primary malignancy, except for malignancies that were radically treated with curative intent prior to the first dose of study intervention and there is no known active disease (more than 5 years, no time limit for dose-escalation phase patients) and a low risk of potential recurrence (e.g., basal cell carcinoma of the skin and squamous cell carcinoma of the skin, which have been treated with potentially curative therapy);\n* Major surgery (excluding placement of central vascular access), radiotherapy within 28 days prior to the first dose (palliative radiotherapy for localized non-target lesions is allowed as long as there is a 14-day washout prior to the day 1 of starting study treatment).\n* Any live or live attenuated vaccine within 28 days prior to the first dose, or the need for a live or live attenuated vaccine is anticipated during the study;\n* Use of antiplatelet therapy including aspirin, adenosine diphosphate (ADP) receptor inhibitors (e.g., clopidogrel), adenosine reuptake inhibitors (e.g., dipyridamole), glycoprotein platelet inhibitors (abciximab), phosphodiesterase inhibitors (cilostazol), and protease-activated receptor (PAR-1) antagonist (vorapaxar), administered for therapeutic purposes within 10 days prior to the first dose;\n* Breastfeeding women;\n* Presence of other serious physical or mental illnesses, abnormal laboratory tests, or other conditions that may increase the risk of participation in the study, affect treatment compliance, or interfere with the results of the study, and which the investigator considers not suitable for participation in this study;\n\nSpecific exclusion criteria for phase II component:\n\n* Patients with any prior grade 2 or higher autoimmune toxicities that are directly related to PD1\u002FPDL1 inhibitor that required the use of immunosuppressive agents including steroids (at dose of \\> prednisolone 10mg daily dose or equivalent dose of other steroids). This may include but not limited to grade 2 or higher autoimmune pneumonitis, hepatitis, pancreatitis, nephritis, myocarditis, neurological, myositis, skin toxicity and hypophysitis.\n* Patients with immune-checkpoint inhibitor related autoimmune thyroid and adrenal insufficiency who are clinically stable on hormonal replacement are not excluded.","ALL","18 Years",{"count":20,"type":21},49,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This study is to determine the activity and tolerability of JS207 as a single agent and in combination cohort with chemotherapy. This is an open-labelled, phase Ib\u002FII study of JS207 in patients with previously treated recurrent or metastatic nasopharyngeal carcinoma. The study will comprise of two phases:\n\n* Phase 1b monotherapy: Consisting of a dose escalation and then expansion phase in patients with recurrent\u002F metastatic (R\u002FM) NPC, who have failed at least 1 prior line of platinum-based chemotherapy, with or without prior treatment with PD1\u002F PDL1 inhibitor.\n* Randomized phase II: Combination of JS207 with capecitabine or paclitaxel in platinum-refractory patients: Patients who have failed one prior line of platinum-based chemotherapy for R\u002FM NPC will be treated with JS207 in combination with capecitabine.\n\nAs phase I portion of the study was completed, the starting dose of JS207 for phase II portion will be 10mg\u002Fkg IV every 3 weeks.",[27],"Recurrent\u002F Metastatic NPC","RECRUITING","2026-07-10",{"date":31,"type":32},"2026-07-13","ACTUAL",{"date":34,"type":32},"2026-06-29",{"date":36,"type":21},"2028-06-30",{"name":38,"class":39},"Chinese University of Hong Kong","OTHER",1,{"id":42,"slug":43,"hasResults":12,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":47,"sex":48,"minAge":18,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},"100053426","prenatal-music-exposure-to-enhance-postnatal-language-development-100053426","NCT07699536","Prenatal Music Exposure to Enhance Postnatal Language Development","Inclusion Criteria:\n\n* residents of the Greater Bay Area (GBA) with Cantonese and\u002For Putonghua being the primary home language(s)\n* aged 18 years or above\n* single fetus pregnancy\n* Less than 32 weeks of gestation",true,"FEMALE",{"count":50,"type":21},480,[52],"NA","The goal of this randomized controlled study is to evaluate the effect of prenatal music exposure on infants through two years of age.\n\nThe study addresses two primary questions:\n\n* Whether prenatal music exposure enhances neural encoding of speech and improve language and cognitive outcomes during the first two years of life among fetuses\n* Whether predictive models can be developed from available fetal data to forecast individual differences in developmental outcomes among fetuses exposed to prenatal music.\n\nParticipants will engage in music listening or self-learning five days a week until delivery. After the participants give birth, the children will be followed up on their neural responses to speech, as well as their language and cognitive development, until they reach two years of age.\n\nThe investigators will compare the effects of low- and high-dose prenatal music exposure with a control group receiving education and develop models to predict outcomes in fetuses exposed to prenatal music.",[55],"Pregnancy",[57,58,59,60,61,62,55,63],"Neural encoding","Prenatal music","Language","Cognitive","EEG","Music exposure","Predictive model","2026-07-08",{"date":31,"type":32},{"date":67,"type":32},"2025-09-15",{"date":69,"type":21},"2030-04",{"name":38,"class":39},2,{"id":73,"slug":74,"hasResults":12,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":82,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":87,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":40},"100054267","efficacy-of-digital-cognitive-behavioral-therapy-for-insomnia-cbt-i-utilizing-embodied-artificial-intelligence-agent-in-virtual-reality-100054267","NCT07699042","Efficacy of Digital Cognitive Behavioral Therapy for Insomnia (CBT-I) Utilizing Embodied Artificial Intelligence Agent in Virtual Reality","Efficacy of Digital Cognitive Behavioral Therapy for Insomnia (CBT-I) Utilizing Embodied Artificial Intelligence Agent in Virtual Reality: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Adults of Chinese ethnicity, aged between 18 and 65 years.\n* Presence of insomnia, as indicated by a score of 10 or higher on the ISI.\n* Meeting the DSM-IV-TR diagnostic criteria for insomnia disorder. The 1-month duration criterion in DSM-IV-TR rather than the 3-month criterion in DSM-V is adopted to broaden the clinical relevance of the study findings.\n* Willing to provide online informed consent to participate in the study.\n* Willing to comply with the requirements outlined in the study protocol.\n* Possession of a smartphone and consistent internet access for smartphone use.\n* Acceptance of the terms of service and privacy policies of the mobile apps used for intervention delivery.\n\nExclusion Criteria:\n\n* A current or history of any sleep disorders other than insomnia disorder, such as narcolepsy, obstructive sleep apnea, and restless legs syndrome.\n* A current or history of mental retardation or neuropsychiatric disorders other than depression or anxiety or stress disorders (as they are considered treatment outcomes), including bipolar disorder, schizophrenia, and substance use disorder.\n* Presence of serious suicidality, demonstrated by ideation with a plan or a previous suicide attempt.\n* Currently receiving long-term pharmacological treatment, including sleep-promoting agents.\n* Currently undergoing structured psychotherapy.\n* A current or history of significant visual, auditory, or balance impairment.\n* A current or history of epilepsy\n* Subject who is preparing for pregnancy or pregnant\n* A current or history of any voice, speech, language disorders and learning difficulties.\n* A current or history of severe health conditions (e.g., stroke, heart attack)\n* Engaged in shiftwork or trans-meridian travel within the past 3 months or during the study.","65 Years",{"count":81,"type":21},168,[52],"The goal of this clinical trial is to evaluate whether a virtually embodied artificial intelligence (AI) agent delivered via VR-enhanced digital cognitive behavioral therapy for insomnia (dCBT-I) can improve insomnia outcomes and treatment adherence in adults with insomnia.\n\nThe main questions it aims to answer are:\n\n\\- Does VR-enhanced dCBT-I with an embodied AI agent lead to greater improvements in insomnia symptoms compared to app-based dCBT-I with an AI chatbot at post-intervention and 3-month follow-up?\n\nResearchers will compare VR-enhanced dCBT-I with an embodied AI agent to app-based dCBT-I with an AI chatbot to see if the VR-enhanced intervention results in significantly improved clinical outcomes and adherence.\n\nParticipants will:\n\n* Be randomly assigned to either the VR-enhanced AI agent intervention group or the app-based AI chatbot control group\n* Complete a digital cognitive behavioral therapy for insomnia (dCBT-I) program with either a virtually embodied AI agent (VR-based) or a chatbot-based application\n* Undergo assessments at baseline, post-intervention, and 3-month follow-up",[85],"Insomnia","NOT_YET_RECRUITING",{"date":31,"type":32},{"date":89,"type":21},"2026-10-23",{"date":91,"type":21},"2029-04-22",{"name":38,"class":39},{"id":94,"slug":95,"hasResults":12,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":100,"enrollmentInfo":101,"targetDuration":4,"studyType":22,"phases":103,"briefSummary":104,"conditions":105,"keywords":109,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":113,"leadSponsor":115,"locationsCount":4},"100645046","digital-insomnia-and-circadian-therapy-for-reducing-depression-symptoms-in-college-students-100645046","NCT07677930","Digital Insomnia and Circadian Therapy for Reducing Depression Symptoms in College Students","Prevent Worsening of Depressive Symptoms Using Digital Cognitive Behavioral Therapy for Insomnia and Circadian Intervention in College Students","Inclusion Criteria:\n\n* Youths aged between 18-24 years old.\n* Insomnia disorders as determined by DSM-5 criteria with a predominant complaint of difficulty initiating sleep.\n* Presence of an evening chronotype according to the score on the Horne-Östberg Morning-Eveningness Questionnaire (MEQ) and having a late bedtime of 12:00 am\u002Fmidnight or later for at least 3 nights per week in the last 3 months.\n* Presented with at least subclinical depressive symptoms as determined by Patient Health Questionnaire-9 ≥ 10.\n* Accessibility to a smartphone.\n\nExclusion Criteria:\n\n* Having a diagnosed sleep disorder that may potentially contribute to the disruption of sleep quantity and quality other than insomnia and delayed sleep phase syndrome, as ascertained by Structured Diagnostic Interview for Sleep patterns and Disorders (DISP), such as restless leg syndrome and OSA, and narcolepsy.\n* Diagnosed with neuropsychiatric disorders such as major depressive disorder, anxiety disorders, bipolar affective disorders, schizophrenia, moderate or above suicidality.\n* Concurrent, regular use of medications known to affect sleep continuity and quality, including both Western medications (e.g. hypnotics, steroids, antidepressants, antihistamines) and over-the-counter medications (e.g. melatonin).\n* Participate in other psychotherapy (e.g., CBT, mindfulness) currently or in the past three months.","24 Years",{"count":102,"type":21},195,[52],"Depression is a leading cause of global disease burden, poor quality of life, disability and suicide, and commonly occurs in adolescence and early adulthood. Insomnia and circadian factors were regarded as potential targets for preventing worsening of depressive symptoms. Additionally, digital insomnia treatment reduces depressive symptoms but is insufficient for individuals with an evening chronotype. Circadian intervention is an adjunctive treatment for sleep disturbance and depression, but is often overlooked. In this study, we aim to evaluate the effect of guided digital insomnia and circadian intervention (dCBT-I + dCI) in reducing depressive symptoms in college students with insomnia and an evening chronotype compared with digital insomnia intervention alone (dCBT-I) and a health education group (dHE). We also aim to develop and evaluate multimodal prediction models to identify individuals who are more or less likely to respond to the interventions, using clinical, behavioral, circadian, and digital engagement data.",[106,85,107,108],"Eveningness","Circadian Rhythm","Depressed Mood",[106,85,108,107],{"date":111,"type":32},"2026-07-01",{"date":111,"type":21},{"date":114,"type":21},"2029-06-30",{"name":38,"class":39},{"id":117,"slug":118,"hasResults":12,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":4,"eligibilityCriteria":122,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":123,"enrollmentInfo":124,"targetDuration":4,"studyType":22,"phases":126,"briefSummary":128,"conditions":129,"keywords":131,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":40},"100643873","phase-4-anti-inflammation-treatment-for-idiopathic-inflammatory-myopathies-100643873","NCT07668505","Anti-inflammation Treatment for Idiopathic Inflammatory Myopathies","A Novel Anti-inflammation Treatment for Idiopathic Inflammatory Myopathies","Inclusion Criteria:\n\n1. ≥18 to \\\u003C80 years of age\n2. Myositis disease onset \\>18 years\n3. Fulfillment of 2017 American College of Rheumatology\u002FEuropean League Against Rheumatism (ACR\u002FEULAR) IIM classification criteria\n4. Active myositis defined as Manual Muscle Testing 8 (MMT8) score \\\u003C142 with at least two other abnormal International Myositis Assessment \\& Clinical Studies Group (IMACS) core set measures (Visual Analogue Scale (VAS) of patient global activity ≥2 cm, physician's global disease activity ≥2 cm, at least one muscle enzyme \\>1.5 times upper limit of normal, Health ssessment Questionnaire(HAQ) ≥0.25), despite 2 additional immunosuppressive treatments on top of glucocorticoids.\n\nExclusion Criteria:\n\n1. Pregnancy or lactation,\n2. Malignancy\n3. Functional class 4\n4. Contraindication to Maraviroc.","80 Years",{"count":125,"type":21},10,[127],"PHASE4","The goal of this clinical trial is to learn if the drug Maraviroc works to treat refractory idiopathic inflammatory myopathy (myositis) in patients who have not responded well to traditional therapies. It will also learn about how the drug affects muscle inflammation and function. The main questions it aims to answer are: Does Maraviroc reduce inflammation in the muscles? Does Maraviroc improve patients' muscle function and overall clinical symptoms? This is an open-label study, meaning researchers will give Maraviroc to all participants (there is no placebo) to see if the drug works to treat refractory myositis. Participants will: Take a 300mg Maraviroc tablet every day for 12 weeks. Undergo exams and tests with their doctors to check their muscle function, symptom improvement, and specific health markers (like enzyme levels).",[130],"Myositis",[132,133,134,135],"myositis","anti-inflammation","CCR5","Maraviroc","2026-06-26",{"date":138,"type":32},"2026-06-30",{"date":140,"type":21},"2026-09-01",{"date":142,"type":21},"2029-08-31",{"name":38,"class":39},{"id":145,"slug":146,"hasResults":12,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":150,"eligibilityCriteria":151,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":79,"enrollmentInfo":152,"targetDuration":4,"studyType":22,"phases":154,"briefSummary":155,"conditions":156,"keywords":159,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":71},"100644979","duodenal-jejunal-bypass-sleeve-djbs-for-obesity-and-metabolic-syndrome-100644979","NCT07675122","Duodenal-jejunal Bypass Sleeve (DJBS) for Obesity and Metabolic Syndrome","Endoscopic Duodenal-jejunal Bypass Sleeve for Treatment of Obesity and Metabolic Syndrome - a Multicenter Pilot Study","DJBS-OMS","Inclusion Criteria:\n\n* Body mass index (BMI) ≥27.5kg\u002Fm2; or BMI ≥25 kg\u002Fm2 with metabolic syndrome\n\nExclusion Criteria:\n\n* Patients who have lost more than 5 kg of weight in the past three months\n* Patients who have used glucagon-like peptide-1 receptor agonists (GLP-1RAs) in the past three months\n* Patients who are currently taking weight loss drugs such as orlistat\n* Those who have taken antiplatelet drugs or anticoagulant drugs such as aspirin in the past month\n* iron deficiency or iron deficiency anemia\n* Gastrointestinal malformations, such as patients with gastrointestinal atresia or other patients who will cause gastrointestinal implantation failure\n* Those with a history of cholecystitis and liver abscess\n* There is a known infection, and the type of disease and the severity of the infection are not suitable for use by clinicians\n* coagulation dysfunction;\n* Severe liver and kidney dysfunction, AST \u002FALT \\> 2.5 times, total bilirubin \\> 35 μmol\u002FL, blood creatinine concentration greater than 180 μmol\u002FL\n* Patients with ASA IV \\& V\n* Drug or alcohol abuse addiction or suffering from uncontrollable mental illness\n* Duodenal bulb ulcer, gastric ulcer or previous and existing pancreatitis\n* Coronary heart disease, angina, cardiac function grade III or above, or pulmonary dysfunction\n* Patients who have undergone ERCP before\n* Patients with potential bleeding or telangiectasia in the stomach, esophagus, small intestine and other parts\n* Have a history of systemic lupus erythematosus, scleroderma\n* Those who have contraindications to endoscopy (judged by clinicians)\n* Pregnant women or those who are preparing to become pregnant\n* Those who are allergic to nickel-titanium\n* Any other situation that the clinician deems unsuitable for participation in this product",{"count":153,"type":21},20,[52],"This study is designed to evaluate the efficacy, safety, and mechanisms of duodenal-jejunal bypass sleeve in patients with obesity",[157,158],"Obesity","Metabolic Syndrome (MetS)",[160,161,162],"duodenal-jejunal bypass sleeve","DJBS","DJBL","2026-06-25",{"date":138,"type":32},{"date":166,"type":21},"2026-08-01",{"date":168,"type":21},"2029-07-31",{"name":38,"class":39},{"id":171,"slug":172,"hasResults":12,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":176,"eligibilityCriteria":177,"healthyVolunteers":47,"sex":17,"minAge":18,"maxAge":178,"enrollmentInfo":179,"targetDuration":4,"studyType":22,"phases":181,"briefSummary":182,"conditions":183,"keywords":185,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":40},"100644186","isometric-resistance-exercise-on-accelerated-atherosclerosis-in-hypertension-100644186","NCT07665034","Isometric Resistance Exercise on Accelerated Atherosclerosis in Hypertension","The Impact of Isometric Resistance Exercise on Accelerated Atherosclerosis in Hypertension: A Study of Randomized Controlled Trial","IRE-HT","Inclusion Criteria:\n\n1. asymptomatic clinically stable adults\n2. aged 18-75 years\n3. Both genders\n4. Suboptimal BP (on stable medication) with SBP 135-160mmHG on ambulatory BP monitoring (AMBP)\n5. Agreeable to no drug changes in coming 1 year 24 weeks\n6. Agreeable to provide informed written consent form\n7. Agreeable to have AMBP and ultrasonic (FMD \\& IMT) scan third (baseline, 24 weeks and preferably 1 year)\n\nExclusion Criteria:\n\n1. relative contraindications to AMBP (e.g. atrial fibrillation)\n2. severe osteoarthritis of knee\n3. known secondary HT\n4. pregnancy\u002Fbreastfeeding\n5. active malignancy\n6. Serious coronary profiles, (unstable angina), renal or hepatic derangement\n7. Need to change medications for control BP at 24 weeks ( SBP\\>160 mmHg)","75 Years",{"count":180,"type":21},200,[52],"Background:\n\nHypertension (HT) is the most common condition worldwide, predisposing to atherosclerotic disease. However, most HT patients have suboptimal BP control despite anti-HT medications. Isometric resistance exercise (IRE) (e.g. wall squat) may improve BP control, characterized by sustained muscle contraction with minimal change in muscle length and joint angle. Most randomized trials of IRE are short duration and their long-term effects on BP and atherosclerotic complications, particularly in the Chinese, remain unknown.\n\nStudy objectives:\n\n(i) To evaluate the impact of IRE on Clinic and Ambulatory BP (AMBP) in Hong Kong Chinese.\n\n(ii) To evaluate the impact of IRE on atherogeneisis surrogates (brachial flow-mediated dilation, FMD and carotid intima-media thickness IMT).\n\n(iii) To evaluate the impact of IRE on mechanisms of BP reduction, including endothelial function FMD, carotid IMT, inflammatory parameters and arterial wall stiffness (cfPWV).\n\nSetting:\n\nRandomized samples of 200 HT patients, aged 18-75 years with systolic BP 135-160mHg while on no or stable anti-HT medications.\n\nDesign: Randomized controlled IRE trial - stratified randomization with randomization block size of 4.\n\n1. 100 patients for wall squat exercise of 14 mins each session (2 mins IRE x 4 sets, 2 mins rest in between), 3 sessions per week, for 1 year, plus advice on healthy diet and lifestyle.\n2. 100 control patients (usual care) with advice on diet and healthy lifestyles and simple stretching exercise programme (yoga) for 1 year.\n\nAll patients will be invited to continue their exercise programme and return for follow up FMD and carotid IMT at 24 weeks and 1 year, and PWV at 24 weeks.\n\nMain outcome measures:\n\n1. BP - Clinic BP and Ambulatory BP parameters at baseline, 12 weeks and 24 weeks. (primary outcome)\n2. Brachial FMD and carotid IMT at baseline, 24 weeks and 1 year. (primary outcome)\n3. Carotid-femoral pulse wave velocity (cf-PWV) at baseline and 24 weeks.\n4. Important atherosclerosis risk factor parameters at baseline, 24 weeks and 1 year - including fasting serum glucose, lipid profiles, HgbA1-C, creatinine, hs-CRP, CBP, fibrinogen, and interleukin 6 (IL-6).\n5. Safety profiles (if any) including CVS event and hospitalization at 1 year.\n\nExpected results: IRE Intervention versus control group, (i) 3mHg more reduction in SBP (Clinic and AMBP). (ii) A group absolute difference in FMD of 1%, and in carotid IMT of 0.06mm between the 2 treatment groups.\n\nImplications: IRE as suggested will be beneficial to management of HT, and will be of great importance in health care of this common disorder in both primary and secondary preventions of atherosclerosis diseases.",[184],"Atherosclerosis Cardiovascular Disease",[186,187,188,189,190,191],"Isometric Resistance Exercise","Essential Hypertension","Atherosclerosis","Brachial FMD","Carotid IMT","Atherosclerosis Prevention","2026-06-23",{"date":194,"type":32},"2026-06-24",{"date":196,"type":32},"2025-10-15",{"date":198,"type":21},"2027-07-30",{"name":38,"class":39},{"id":201,"slug":202,"hasResults":12,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":4,"eligibilityCriteria":206,"healthyVolunteers":12,"sex":207,"minAge":208,"maxAge":123,"enrollmentInfo":209,"targetDuration":4,"studyType":22,"phases":211,"briefSummary":212,"conditions":213,"keywords":215,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":224},"100644456","steam-map-1-study---steam-therapy-with-mri-and-ai-assisted-planning-100644456","NCT07663344","STEAM-MAP 1 Study - Steam Therapy With MRI and AI-assisted Planning","Prospective Feasibility Trial on MRI-TRUS Fusion Water Vapour Ablation for Benign Prostatic Hyperplasia (STEAM-MAP 1 Study - Steam Therapy With MRI and AI-assisted Planning)","Inclusion Criteria:\n\n* Age 30-80 years old with symptomatic BPH.\n* Prostate volume 30-80 mL (TRUS\u002FMRI\u002FUS)\n* Suitable for Rezum.\n* Able to consent and comply with follow-up to 1 month.\n* With prior prostate MRI within 2 years\n\nExclusion Criteria:\n\n* Known\u002Fsuspected prostate cancer requiring oncologic management.\n* Prior prostate surgery impacting urethral anatomy within 12 months.\n* Prior implant affecting urethral anatomy.\n* Active UTI or untreated bacteriuria pre-op.\n* Uncorrectable coagulopathy; inability to manage antithrombotics.\n* Severe medical comorbidity precluding endoscopy.","MALE","30 Years",{"count":210,"type":21},15,[52],"The STEAM-MAP 1 Study is a single-arm, prospective feasibility trial evaluating the integration of MRI-transrectal ultrasound (TRUS) fusion guidance into Rezūm water vapor thermal therapy for men with symptomatic benign prostatic hyperplasia (BPH).",[214],"Benign Prostatic Hyperplasia (BPH)",[216],"Water vapor thermal therapy","2026-06-22",{"date":192,"type":32},{"date":220,"type":21},"2026-06-01",{"date":222,"type":21},"2028-03-31",{"name":38,"class":39},3,{"id":226,"slug":227,"hasResults":12,"nctId":228,"briefTitle":229,"officialTitle":230,"acronym":231,"eligibilityCriteria":232,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":233,"enrollmentInfo":234,"targetDuration":4,"studyType":22,"phases":235,"briefSummary":236,"conditions":237,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":240,"startDateStruct":241,"completionDateStruct":242,"leadSponsor":244,"locationsCount":40},"100642036","endoscopic-sleeve-gastroplasty-plus-duodenal-pulsendo-for-obese-t2dm-100642036","NCT07660445","Endoscopic Sleeve Gastroplasty Plus Duodenal pulsENDO for Obese T2DM","Integrating Duodenal Recellularization Via Electroporation Therapy and Endoscopic Sleeve Gastroplasty as a Novel Approach to Managing Diabesity (DRAGON Study)","DRAGON","Inclusion Criteria:\n\n* BMI \\>\u002F= 27kg\u002Fm2\n* Known T2DM\n* Individualized Metabolic Surgery (IMS) score 25-115\n* HbA1c \\\u003C11% (subjects on oral glucose lowering drug(s) or HbA1c \\\u003C8% (subjects on insulin)\n\nExclusion Criteria:\n\n* Previous treatment with ReCET, ESG or similar procedure\n* Previous GI surgery that could preclude the ability to perform ReCET or ESG, or acute gastric and duodenal pathology that increased the risk of ReCET or ESG\n* Type 1 DM, DM secondary to specific disease or having any history of ketoacidosis\n* Fasting C-peptide level \\\u003C0.5ug\u002FL\n* Any inflammatory disease of the gastrointestinal tract such as Crohn's disease\n* Abnormal pathologies or conditions of the gastrointestinal tract, including duodenal polyps, ulcers or upper gastrointestinal bleeding conditions within 3 months of study\n* Uncorrectable bleeding diathesis, platelet dysfunction, thrombocytopenia with platelet count less than 100,000\u002Fmicroliter or known coagulopathy\n* Currently taking prescription antithrombotic therapy (e.g., anticoagulant agent) within 10 days prior to study and\u002For there is a need or expected need to use during the study period\n* Currently taking medications known to cause significant weight gain or weight loss (e.g. chemotherapeutics)\n* Patients who have used non-steroidal analgesics and anti-inflammatory drugs (NSAID) and corticosteroids in the past 1 month\n* Underlying uncontrolled endocrine problem that leads to obesity, including and not limited to hypothyroidism, Cushing syndrome and eating disorder.\n* Patients with contra-indications to endoscopy\n* Patients with cirrhosis due to causes other than MASLD\n* Malignancy\n* Diagnosis of autoimmune connective tissue disorder (e.g. lupus erythematosus, scleroderma)\n* Pregnant or breast feeding\n* ASA grade IV \\& V\n* Mental or psychiatric disorder; Drug or alcohol addiction\n* Other cases deemed by the examining physician as unsuitable for safe treatment\n* Refusal to participate","70 Years",{"count":153,"type":21},[52],"This study is designed to evaluate the efficacy, safety, and mechanisms of combining ESG and pulsENDO procedure in obese patients with T2DM",[238],"Obesity Type 2 Diabetes Mellitus","2026-06-20",{"date":194,"type":32},{"date":166,"type":21},{"date":243,"type":21},"2031-07-31",{"name":38,"class":39},{"id":246,"slug":247,"hasResults":12,"nctId":248,"briefTitle":249,"officialTitle":250,"acronym":251,"eligibilityCriteria":252,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":233,"enrollmentInfo":253,"targetDuration":4,"studyType":22,"phases":255,"briefSummary":256,"conditions":257,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":260,"startDateStruct":261,"completionDateStruct":262,"leadSponsor":264,"locationsCount":40},"100622961","duodenal-pulsendo-for-suboptimally-controlled-type-ii-diabetes-mellitus-and-steatotic-liver-disease-100622961","NCT07390422","Duodenal pulsENDO for Suboptimally Controlled Type II Diabetes Mellitus and Steatotic Liver Disease","Duodenal Recellularization Via Electroporation Therapy for Suboptimally Controlled Type II Diabetes Mellitus and Steatotic Liver Disease (DRESS-1 Study)","DRESS-1","Inclusion Criteria:\n\n* Duration of T2DM \\\u003C 10 years\n* BMI 18.5-40kg\u002Fm2\n* Failure to achieve adequate HbA1c reduction (7.5 - 11%) after at least 3 months stable dosage of oral glucose lowering drugs\n\nExclusion Criteria:\n\n* Previous treatment with pulsENDO or similar procedure\n* Previous GI surgery that could preclude the ability to perform pulsENDO, or acute gastric and duodenal pathology that increased the risk of pulsENDO\n* Type 1 DM, DM secondary to specific disease or having any history of ketoacidosis\n* Patients on insulin\n* Fasting C-peptide level \\\u003C0.5ug\u002FL\n* Any inflammatory disease of the gastrointestinal tract such as Crohn's disease\n* Abnormal pathologies or conditions of the gastrointestinal tract, including duodenal polyps, ulcers or upper gastrointestinal bleeding conditions within 3 months of study\n* Uncorrectable bleeding diathesis, platelet dysfunction, thrombocytopenia with platelet count less than 100,000\u002Fmicroliter or known coagulopathy\n* Currently taking prescription antithrombotic therapy (e.g., anticoagulant or antiplatelet agent) within 10 days prior to study and\u002For there is a need or expected need to use during the study period\n* Currently taking medications known to cause significant weight gain or weight loss (e.g. chemotherapeutics)\n* Patients who have used non-steroidal analgesics and anti-inflammatory drugs (NSAID) and corticosteroids in the past 1 month\n* Underlying uncontrolled endocrine problem that leads to obesity, including and not limited to hypothyroidism, Cushing syndrome and eating disorder.\n* Patients with contra-indications to endoscopy\n* Patients with cirrhosis due to causes other than MASLD\n* Malignancy\n* Diagnosis of autoimmune connective tissue disorder (e.g. lupus erythematosus, scleroderma)\n* Pregnant or breast feeding\n* ASA grade IV \\& V\n* Mental or psychiatric disorder; Drug or alcohol addiction\n* Other cases deemed by the examining physician as unsuitable for safe treatment\n* Refusal to participate",{"count":254,"type":21},40,[52],"This study is designed to evaluate the efficacy, safety, and mechanisms of pulsENDO procedure in patients with T2DM and its effect on MASLD.",[258,259,158],"T2DM (Type 2 Diabetes Mellitus)","MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease",{"date":194,"type":32},{"date":140,"type":21},{"date":263,"type":21},"2033-08-30",{"name":38,"class":39},{"id":266,"slug":267,"hasResults":12,"nctId":268,"briefTitle":269,"officialTitle":270,"acronym":271,"eligibilityCriteria":272,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":273,"enrollmentInfo":274,"targetDuration":4,"studyType":22,"phases":275,"briefSummary":276,"conditions":277,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":280,"startDateStruct":281,"completionDateStruct":282,"leadSponsor":284,"locationsCount":40},"100621889","duodenal-pulsendo-as-an-early-treatment-for-type-2-dm-100621889","NCT07376486","Duodenal pulsENDO as an Early Treatment for Type 2 DM","Duodenal Recellularization Via Electroporation Therapy as an Early Treatment for Type 2 Diabetes Mellitus (DREAM-1 Study)","DREAM-1","Inclusion Criteria:\n\n* Duration of T2DM \\\u003C\u002F= 2 years\n* HbA1c \\\u003C\u002F= 7.5%\n* On 0-1 oral diabetes medications\n\nExclusion Criteria:\n\n* Previous treatment with pulsENDO or similar procedure\n* Previous GI surgery that could preclude the ability to perform pulsENDO, or acute gastric and duodenal pathology that increased the risk of pulsENDO\n* Type I DM, DM secondary to specific disease or having any history of ketoacidosis\n* Fasting C-peptide level \\\u003C0.5ug\u002FL\n* Any inflammatory disease of the gastrointestinal tract such as Crohn's disease\n* Abnormal pathologies or conditions of the gastrointestinal tract, including duodenal polyps, ulcers or upper gastrointestinal bleeding conditions within 3 months of study\n* Uncorrectable bleeding diathesis, platelet dysfunction, thrombocytopenia with platelet count less than 100,000\u002Fmicroliter or known coagulopathy\n* Currently taking prescription antithrombotic therapy (e.g., anticoagulant or antiplatelet agent) within 10 days prior to study and\u002For there is a need or expected need to use during the study period\n* Currently taking medications known to cause significant weight gain or weight loss (e.g. chemotherapeutics)\n* Patients who have used non-steroidal analgesics and anti-inflammatory drugs (NSAID) and corticosteroids in the past 1 month\n* Underlying uncontrolled endocrine problem that leads to obesity, including and not limited to hypothyroidism, Cushing syndrome and eating disorder.\n* Patients with contra-indications to endoscopy\n* Malignancy\n* Diagnosis of autoimmune connective tissue disorder (e.g. lupus erythematosus, scleroderma)\n* Pregnant or breast feeding\n* ASA grade IV \\& V\n* Mental or psychiatric disorder; Drug or alcohol addiction\n* Other cases deemed by the examining physician as unsuitable for safe treatment\n* Refusal to participate","60 Years",{"count":254,"type":21},[52],"This study is designed to evaluate the efficacy and safety of endoscopic duodenal re-cellularization therapy using pulsed electric field in individuals with in patients with a recent diagnosis of type 2 diabetes mellitus (T2DM).",[278,279],"Diabete Mellitus","T2 Diabetes and Fatty Liver Disease (Non-alcoholic Origin)",{"date":194,"type":32},{"date":140,"type":21},{"date":283,"type":21},"2032-08-30",{"name":38,"class":39},{"id":286,"slug":287,"hasResults":12,"nctId":288,"briefTitle":289,"officialTitle":290,"acronym":4,"eligibilityCriteria":291,"healthyVolunteers":47,"sex":17,"minAge":18,"maxAge":233,"enrollmentInfo":292,"targetDuration":4,"studyType":22,"phases":294,"briefSummary":295,"conditions":296,"keywords":298,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":302,"startDateStruct":303,"completionDateStruct":305,"leadSponsor":307,"locationsCount":40},"100524487","a-stepped-care-model-to-deliver-cbt-i-in-community-100524487","NCT06109363","A Stepped Care Model to Deliver CBT-I in Community","Effectiveness of a Stepped Care Model to Deliver Cognitive-behaviour Therapy for Insomnia in Adults, a Pragmatic Stepped-wedge Cluster Randomized Trial","Inclusion Criteria:\n\n1. Chinese adults aged 18-70 years old,\n2. The score of Insomnia Severity Index ≥ 10.\n\nExclusion Criteria:\n\n1. present with psychotic disorders such as bipolar disorder and schizophrenia,\n2. present with severe depression or suicidal ideation,\n3. present with neurodegenerative diseases that prevent participant from completing the intervention (e.g., dementia and Parkinson's disease).\n4. unable to provide consent",{"count":293,"type":21},1100,[52],"Insomnia is one of the most common sleep disorders and affects approximately 10 - 40% of the population across different age groups in Hong Kong. Cognitive behavioral therapy for insomnia (CBT-I) is the first line treatment for adult insomnia due to its comparable effect to medication in short term but is more sustainable in the long run. However, only a few sufferers have received CBT-I, due to limited accessibility, lack of trained sleep therapists, time costing and geographical limitations. To increase CBT-I accessibility, different formats of CBT-I have been proposed. Empirical evidence including ours consistently suggested that self-help digital CBT-I is effective in improving sleep while its augmentation with a guided approach could further enhance the treatment gain. Previous evidence has suggested that although self-help CBT-I could lead to positive outcomes, the drop out rate is quite high and maybe less effective for patients with comorbidity or high level of distress.\n\nThus, a stepped-care approach to CBT-I that utilizes online self help and therapist-guided modes of delivery might be a potential way to facilitate efficient dissemination of effective insomnia treatment resources. The effectiveness of the stepped care model will be evaluated in a real world setting using stepped-wedge cluster randomized controlled design. The program will be rolled out to different districts in Hong Kong sequentially in 18 districts over 4 steps with a eqaully spaced time periods.",[85,297],"Sleep Disturbance",[85,299,300],"Stepped care model","Stepped wedge cluster randomized trial","2026-06-19",{"date":194,"type":32},{"date":304,"type":32},"2023-10-23",{"date":306,"type":21},"2027-04-22",{"name":38,"class":39},{"id":309,"slug":310,"hasResults":12,"nctId":311,"briefTitle":312,"officialTitle":312,"acronym":4,"eligibilityCriteria":313,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":314,"targetDuration":4,"studyType":315,"phases":4,"briefSummary":316,"conditions":317,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":319,"lastUpdatePostDateStruct":320,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":325,"locationsCount":40},"100644362","clinical-course-and-biomarkers-associated-with-nonalcoholic-fatty-liver-disease-nafld-in-chinese-patients-with-obesity-100644362","NCT07662356","Clinical Course and Biomarkers Associated With Nonalcoholic Fatty Liver Disease (NAFLD) in Chinese Patients With Obesity","Inclusion Criteria:\n\n* Age 18 years or above\n* Chinese ethnicity\n* Patient undergoing obesity surgery at The Prince of Wales Hospital\n\nExclusion Criteria:\n\n* Endocrine causes of obesity\n* Active uncontrolled psychiatric illness\n* Active substance abuse\n* Alcohol intake exceeding 30 grams per day in males or 20 grams per day in females\n* Presence of other co-existing liver disease, as evidenced by known history of positive viral hepatitis serology\n* History of decompensated liver disease\n* Unlikely to comply with management protocol\n* Failure to give consent",{"count":180,"type":21},"OBSERVATIONAL","Nonalcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease in many parts of the world. NAFLD can progress to nonalcoholic steatohepatitis (NASH) and result in cirrhosis and liver cancer. Despite NAFLD is common, there are a lot of knowledge gaps about this common disease including the progression from NAFLD to NASH and from fibrosis to cirrhosis, efficacious treatment strategies, etc.\n\nIn this study, we aim to investigate the clinical course and biomarkers associated with NAFLD in a group of obese patients with or without known history of NAFLD at baseline undergoing laparoscopic bariatric surgery. During laparoscopic surgery, subjects consented to participate will have liver biopsies performed under direct vision and sent for histological analysis and scoring. The patients will undergo comprehensive clinical and biochemical assessment before and after the surgical procedures.\n\nThe prevalence of NAFLD and clinical course of this group of patients with obesity will be assessed using histology as the gold standard. Clinical characteristics and biomarkers associated with NAFLD will be identified.",[318],"Nonalcoholic Fatty Liver Disease (NAFLD)","2026-06-17",{"date":192,"type":32},{"date":322,"type":32},"2019-12-16",{"date":324,"type":21},"2030-12-31",{"name":38,"class":39},{"id":327,"slug":328,"hasResults":12,"nctId":329,"briefTitle":330,"officialTitle":331,"acronym":4,"eligibilityCriteria":332,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":333,"targetDuration":4,"studyType":315,"phases":4,"briefSummary":335,"conditions":336,"keywords":340,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":347,"lastUpdatePostDateStruct":348,"startDateStruct":350,"completionDateStruct":352,"leadSponsor":354,"locationsCount":40},"100642411","impacts-of-hiv-treatment-regimens-on-archived-drug-resistance-100642411","NCT07643948","Impacts of HIV Treatment Regimens on Archived Drug Resistance","Impact of Antiretroviral Therapy (ART) Switch on Archived HIV-1 Drug Resistance in Virally Suppressed Patients: A Prospective Cohort Study","Inclusion Criteria:\n\n* Patients living with HIV who are (a) aged 18 or above, (b) on antiretroviral therapy, (c) has viral load \\\u003C20 copies\u002FmL at 2 time points for ≥6 months, (d) planning regimen switch.\n* Patients for inclusion in the control group meet the same criteria (a) but they are not planned for switch. Controls include patients with low level viremia (LLV) as defined as ≥2 consecutive viral load level between 21 and 200 copies\u002FmL in the preceding 2 years.\n\nExclusion Criteria:\n\n* Patients living with HIV who (a) are pregnant, (b) have virologic failure, (c) are suffering from concurrent opportunistic infections, (d) are prisoners , (e) are unable to give consent, and (f) have mental illnesses.",{"count":334,"type":21},420,"The study aims to determine the prevalence of drug resistance mutation (DRM) in virally suppressed HIV infection, and the impacts of regimen change and the presence of low level viremia. Adults living with HIV infection on antiretroviral therapy (ART) with full viral suppression would be recruited. Cases are patients planning for regimen switch, while controls are those with and without low level viraemia (LLV) not planned for switch. Blood samples would be collected before and after switch. Sequencing would be performed to identify DRM present in HIV-1 proviral DNA.",[337,338,339],"HIV -1 Infection","Antiretroviral Therapy","Drug Resistance, Microbial",[341,342,343,344,345,346],"antiretroviral therapy","regimen switch","archived resistance","low level viremia","proviral DNA","HIV infection","2026-06-10",{"date":349,"type":32},"2026-06-12",{"date":351,"type":32},"2025-10-01",{"date":353,"type":21},"2029-12-31",{"name":38,"class":39},{"id":356,"slug":357,"hasResults":12,"nctId":358,"briefTitle":359,"officialTitle":360,"acronym":4,"eligibilityCriteria":361,"healthyVolunteers":47,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":362,"targetDuration":4,"studyType":22,"phases":364,"briefSummary":365,"conditions":366,"keywords":369,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":376,"startDateStruct":378,"completionDateStruct":380,"leadSponsor":382,"locationsCount":40},"100571091","theory-based-health-behaviour-change-intervention-in-individuals-of-metabolic-syndrome-with-chronic-kidney-disease-100571091","NCT06715735","Theory-based Health Behaviour Change Intervention in Individuals of Metabolic Syndrome With Chronic Kidney Disease","The Effectiveness of A Theory-based Health Behaviour Change Intervention on Waist Circumference and Kidney Function in Patients of Metabolic Syndrome With Chronic Kidney Disease: A Randomised Controlled Trial","Inclusion Criteria:\n\n* Participants are 18 years old and above;\n* Participants have both diagnoses of MetS based on IDF clinical diagnostic criteria (WC for Chinese: ≥ 90 cm in men and ≥ 80 cm in women, and fulfils two items of the following: TG ≥ 1.7 mmol\u002FL or treatment for hypertriglycerides, HDL-C\\\u003C1.03 mmol\u002FL in men or \\\u003C1.29 mmol\u002FL in women or treatment for low HDL-C, FG ≥5.6 mmol\u002FL or previously diagnosed type 2 diabetes, and BP ≥ 130\u002F85 mmHg or treatment for hypertension), and CKD;\n* Participants are capable of understanding and providing informed consent, their cognitive function will be screened by the abbreviated mental test with a score higher than seven;\n* Own a smartphone for accessing WeChat;\n* Being able to communicate in Chinese.\n\nExclusion Criteria:\n\n* Participants who have medical contraindications to exercise, including walking;\n* Participants who have already started dialysis or kidney transplant;\n* Current participation in another clinical trial related to health behaviour change or medical trial;\n* Participants who have doctor-diagnosed psychiatric illness;\n* Adjustment of medication within half a year;\n* Participants who have performed regular planned exercise (Defined as at least 150 minutes of moderate-intensity aerobic activity or 75 minutes of high-intensity aerobic activity per week, or a combination of moderate-intensity and high-intensity aerobic activity) within the past month.",{"count":363,"type":21},160,[52],"This study will adopt a 2-arm, pretest-posttest, and assessor-blind RCT design to examine the effectiveness of a theory-based health behaviour change intervention on WC (primary outcome), kidney function (eGFR, primary outcome), dietary behaviour, PA, exercise capacity, and self-efficacy of dietary behaviour and PA among Chinese adults with metabolic syndrome and chronic kidney disease.\n\nA total of 160 adults with metabolic syndrome and chronic kidney disease will be recruited, with 80 participants in each group. Data will be collected at 3-time points (baseline, immediate post-intervention and 1-month post-intervention) via an online questionnaire survey platform (Qualtrics) by researchers blinded to the group allocation to reduce the detection bias.",[367,368],"Chronic Kidney Diseases","Metabolic Syndrome",[368,370,371,372,373,374],"Chronic Kidney Disease","Waist Circumference","Kidney Function","Behaviour Change Intervention","Health Action Process Approach","2026-06-09",{"date":377,"type":32},"2026-06-11",{"date":379,"type":32},"2024-12-20",{"date":381,"type":21},"2026-10-30",{"name":38,"class":39},{"id":384,"slug":385,"hasResults":12,"nctId":386,"briefTitle":387,"officialTitle":388,"acronym":4,"eligibilityCriteria":389,"healthyVolunteers":47,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":390,"targetDuration":4,"studyType":22,"phases":391,"briefSummary":392,"conditions":393,"keywords":394,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":395,"startDateStruct":396,"completionDateStruct":398,"leadSponsor":400,"locationsCount":40},"100556643","theory-based-health-behaviour-change-intervention-in-patients-of-metabolic-syndrome-with-chronic-kidney-disease-100556643","NCT06527768","Theory-based Health Behaviour Change Intervention in Patients of Metabolic Syndrome With Chronic Kidney Disease","The Effectiveness of a Theory-based Health Behaviour Change Intervention on Waist Circumference and Kidney Function in Patients of Metabolic Syndrome With Chronic Kidney Disease: A Pilot Randomised Controlled Trial","Inclusion Criteria:\n\n* Participants are 18 years old and above;\n* Participants have both diagnoses of MetS based on IDF clinical diagnostic criteria (WC for Chinese: ≥ 90 cm in men and ≥ 80 cm in women, and fulfils two items of the following: TG ≥ 1.7 mmol\u002FL or treatment for hypertriglycerides, HDL-C\\\u003C1.03 mmol\u002FL in men or \\\u003C1.29 mmol\u002FL in women or treatment for low HDL-C, FG ≥5.6 mmol\u002FL or previously diagnosed type 2 diabetes, and BP ≥ 130\u002F85 mmHg or treatment for hypertension) and CKD;\n* No medical contraindications to exercise, including walking;\n* Participants are capable of understanding and providing informed consent;\n* Own a smartphone for accessing WeChat;\n* Being able to communicate in Chinese;\n* Stay in Chengdu during the study period.\n\nExclusion Criteria:\n\n* Participants who cannot perform brisk walking exercise;\n* Participants who have already started dialysis or kidney transplant;\n* Current participation in another clinical trial related to health behaviour change or medical trial;\n* Participants who have doctor-diagnosed psychiatric illness;\n* Participants who have a cognitive impairment, which will be screened by the abbreviated mental test with a score lower than seven;\n* Adjustment of medication within half a year;\n* Participants who have performed regular planned exercise (Defined as at least 150 minutes of moderate-intensity aerobic activity or 75 minutes of high-intensity aerobic activity per week, or a combination of moderate-intensity and high-intensity aerobic activity) within the past month.",{"count":254,"type":21},[52],"The pilot study will adopt a 2-arm, pretest-posttest, and assessor-blind randomized controlled trial design to examine the feasibility and acceptability of a theory-based health behaviour change intervention and examine its effects on waist circumference (primary outcome), kidney function (estimated glomerular filtration rate, urine albumin-to-creatinine ratio, primary outcome), dietary behaviour, physical activity, exercise capacity and self-efficacy of diet behaviour and physical activity among Chinese adults with metabolic syndrome and chronic kidney disease.\n\nResearchers will compare the theory-based health behaviour change intervention to usual care to see if the theory-based health behaviour change intervention can reduce waist circumference and preserve kidney function over three months.\n\nA total of 40 adults with metabolic syndrome and chronic kidney disease will be recruited, with 20 participants in each group. Data will be collected at two-time points (baseline and immediate post-intervention) via an online questionnaire survey platform (Qualtrics) by researchers blinded to the group allocation to reduce the detection bias.",[367,368],[368,370,371,372,373],{"date":377,"type":32},{"date":397,"type":32},"2024-07-31",{"date":399,"type":21},"2026-07-31",{"name":38,"class":39},{"id":402,"slug":403,"hasResults":12,"nctId":404,"briefTitle":405,"officialTitle":406,"acronym":4,"eligibilityCriteria":407,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":408,"targetDuration":4,"studyType":315,"phases":4,"briefSummary":410,"conditions":411,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":413,"lastUpdatePostDateStruct":414,"startDateStruct":415,"completionDateStruct":416,"leadSponsor":418,"locationsCount":40},"100643486","aortic-dissection-detection-risk-score-with-d-dimer-to-rule-out-acute-aortic-syndrome-100643486","NCT07640334","Aortic Dissection Detection Risk Score With D-dimer to Rule-Out Acute Aortic Syndrome","The Combination of Aortic Dissection Detection Risk Score With D-dimer to Rule-Out Acute Aortic Syndrome: Multicentre Prospective Study in Emergency Departments","Inclusion Criteria:\n\n* Adult patients aged ≥ 18 years; AND\n* Presentation to the ED with any of the following symptoms: acute onset (\\\u003C14 days) chest pain, abdominal pain, back pain, syncope, or signs of malperfusion (e.g. limb ischemia, neurological deficit); AND\n* AAS is considered as a possible differential diagnosis by the treating physician. Enrolment in the study will be determined by the attending physician during initial medical consultation in the ED and prior to establishing a final diagnosis.\n\nExclusion Criteria:\n\n* An alternative diagnosis to AAS established by the treating physician after the initial assessment; OR\n* Trauma cases; OR\n* Patients with a known diagnosis of AAS before the index ED visit (e.g. with a diagnostic imaging done before the ED visit or referral from other institutions for AAS); OR\n* Clinical severity or other conditions not allowing complete evaluation\u002Fproper enrolment; OR\n* Patient who refuse to participate.",{"count":409,"type":21},448,"The goal of this study is to evaluate the safety of integrating the Aortic Dissection Detection Risk Score (ADD-RS) and D-dimer testing for ruling out acute aortic syndrome (AAS) in the emergency department (ED). The main question it aims to answer: Can the combination of the ADD-RS \\\u003C2, and D dimer \\\u003C500ng\u002FmL rule-out AAS in ED patients without CTA? The researchers will recruit patients suspected with AAS in the ED, and the patients will receive a ADD-RS score, a D-dimer testing after signing a written consent.",[412],"Acute Aortic Syndrome","2026-06-08",{"date":347,"type":32},{"date":31,"type":21},{"date":417,"type":21},"2028-12-31",{"name":38,"class":39},{"id":420,"slug":421,"hasResults":12,"nctId":422,"briefTitle":423,"officialTitle":424,"acronym":4,"eligibilityCriteria":425,"healthyVolunteers":47,"sex":17,"minAge":79,"maxAge":4,"enrollmentInfo":426,"targetDuration":4,"studyType":22,"phases":427,"briefSummary":428,"conditions":429,"keywords":435,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":441,"lastUpdatePostDateStruct":442,"startDateStruct":443,"completionDateStruct":444,"leadSponsor":446,"locationsCount":40},"100643409","music-breathing-in-enhancing-resilience-among-elders-at-risk-of-mental-health-problems-100643409","NCT07631845","Music Breathing in Enhancing Resilience Among Elders at Risk of Mental Health Problems","Effects of a Mindfulness-based Music Breathing Intervention in Enhancing Resilience Among Community-dwelling Elders at Risk of Mental Health Problems: A Pilot Randomised Controlled Trial","Inclusion Criteria:\n\n* Aged 65 years or above\n* Able to read Chinese and communicate in Cantonese\u002FMandarin.\n* Has mild to moderate anxiety and\u002For depressive symptoms, based on the - Hospital Anxiety and Depression Scale (HADS) (i.e., a score of 8 or higher on either the anxiety or depression subscale)\n\nExclusion Criteria:\n\n* Partcipants will be excluded if they have cognitive impairment, hearing loss, severe depression, known mental illness, or chronic illness.",{"count":254,"type":21},[52],"The goal of this pilot randomised controlled trial is to examine the effects of a mindfulness-based music breathing intervention in enhancing resilience (primary outcome), and in reducing anxiety, depressive symptoms, loneliness, and improving health-related quality of life (secondary outcomes) among community-dwelling older adults at risk of mental health problems.\n\nIt is hypothesised that compared with the control group, participants in the intervention group will report enhanced resilience, reduced anxiety, depressive symptoms, and loneliness, and improved health-related quality of life immediately post-intervention.",[430,431,432,433,434],"Resilience","Anxiety","Depressive Symptom","Loneliness","Health-related Quality of Life",[436,437,438,439,430,440],"Mindfulness","Msuic","Breathing","Community-dwelling elders","Mental health","2026-06-07",{"date":347,"type":32},{"date":413,"type":32},{"date":445,"type":21},"2026-08-31",{"name":38,"class":39},{"id":448,"slug":449,"hasResults":12,"nctId":450,"briefTitle":451,"officialTitle":452,"acronym":453,"eligibilityCriteria":454,"healthyVolunteers":12,"sex":17,"minAge":455,"maxAge":123,"enrollmentInfo":456,"targetDuration":4,"studyType":22,"phases":458,"briefSummary":459,"conditions":460,"keywords":462,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":464,"lastUpdatePostDateStruct":465,"startDateStruct":467,"completionDateStruct":469,"leadSponsor":471,"locationsCount":71},"100466620","phase-2-glp-1-analogue-in-preventing-progression-of-small-vessel-disease-gapp-svd-100466620","NCT05356104","GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD)","GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD) - A Pilot Study","GAPP-SVD","Inclusion Criteria:\n\n1. Chinese ethnicity;\n2. Age 55 to 80 years old;\n3. Age-Related White Matter Change (ARWMC) Scale of 2 or early 3 in FLAIR MRI;\n4. Modified Functional Ambulation Classification 5 or above;\n5. Montreal Cognitive Assessment (MoCA) score \\\u003C 25;\n6. Both diabetic and non-diabetic patient are eligible;\n7. Patient who understands the purpose and requirements of the study, and able to provide an informed consent;\n\nExclusion Criteria:\n\n1. Dementia or MoCA score lower than 2nd percentile of the age and education adjusted cutoff ;\n2. Cerebral white matter changes unrelated to neurodegenerative, e.g. CADASIL, X-linked adrenoleukodystrophy, metabolic diseases, multiple sclerosis, etc.;\n3. Contraindication to GLP-1R agonist, including thyroid carcinoma, pancreatic pathology, proliferative retinopathy, hypersensitivity to GLP-1R agonist and history of family history of multiple endocrine neoplasia;\n4. BMI \\\u003C18.5kg\u002Fm2;\n5. Contraindication to proposed imaging, e.g. chronic kidney disease (KDNIGO) stage 4 or above, acute kidney injury, hypersensitivity to gadolinium-based contrast, non-MRI conditional implants or prosthesis;\n6. Medical condition that would not allow the patient to adhere to the protocol or complete the study.;\n7. Patient with established neurodegenerative disorders (e.g. Parkinson's Disease, Alzheimer's Disease, etc.);\n8. Pregnancy.","55 Years",{"count":457,"type":21},110,[24],"Cerebral small vessel disease (cSVD), a result of neurovascular cell dysfunction, is a major cause of stroke, dementia and mobility problems worldwide. Vascular risk factor control alone may not be sufficient to prevent the development of vascular cognitive impairment (VCI) in patients with cSVD according to previous clinical trials.\n\nThe presence of glucagon-like peptide-1 receptor (GLP-1R) in cerebral microglia may reveal a potential therapeutic target for prevention of cSVD progression and its disabling clinical outcomes. At the cellular and animal experimentation levels, GLP-1R agonist demonstrated reversal of some pathogenic processes in cSVD. However, its application to cSVD patients remains to be elucidated.\n\nInvestigator aims to investigate the safety and efficacy of GLP-1R agonist in patients with moderate-to-severe cSVD.",[461],"Cerebral Small Vessel Disease",[463],"cSVD","2026-06-03",{"date":466,"type":32},"2026-06-05",{"date":468,"type":32},"2022-05-25",{"date":470,"type":21},"2027-12",{"name":38,"class":39},{"id":473,"slug":474,"hasResults":12,"nctId":475,"briefTitle":476,"officialTitle":477,"acronym":4,"eligibilityCriteria":478,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":479,"targetDuration":4,"studyType":22,"phases":481,"briefSummary":482,"conditions":483,"keywords":485,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":490,"lastUpdatePostDateStruct":491,"startDateStruct":492,"completionDateStruct":493,"leadSponsor":495,"locationsCount":4},"100643454","effect-of-dance-based-multimodal-exercise-for-managing-cipn-in-cancer-patients-100643454","NCT07632482","Effect of Dance-based Multimodal Exercise for Managing CIPN in Cancer Patients","Effects of Dance-based Multimodal Exercise Programme for Managing Chemotherapy-induced Peripheral Neuropathy in Patients With Solid Tumors: A Pilot Randomized Controlled Study","Inclusion Criteria:\n\n* Patients was diagnosed with malignant solid tumor (s) which is defined as abnormal, cancerous masses of tissue, for example, all carcinomas (such as breast cancer, stomach cancer, colorectal cancer and gynecological cancer, lung cancer and so on), sarcomas and lymphomas\n* Patients experience CIPN symptoms\n* Patients are able to use smart phone and WhatsApp\n* Patients are able to read or understand Chinese.\n\nExclusion Criteria:\n\n* Cancer patients suffer from severe organ failure or diseases that limit their level of activity\n* Patients are diagnosed with non-chemotherapy induced peripheral neuropathy, such as sciatica and diabetic neuropathy\n* Patients receive treatments that affect the severity of neuropathy, such as steroid, anticonvulsants and antidepressants\n* Patients age below 18 years old\n* Patients have cognitive impairments.",{"count":480,"type":21},76,[52],"Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a significant and distressing symptom experienced by cancer patients with different cancer types. Systematic reviews demonstrate that exercise is an effective non-pharmacological strategy for managing chemotherapy-induced peripheral neuropathy (CIPN) in cancer patients. Multimodal exercise was found to be superior to a single-modality exercise programme. However, the lack of using Information-Motivation-Behavioral Skill (IMB) model and addressing the social motivation component in current multimodal exercise programmes for cancer patients with solid tumors.\n\nObjectives: This study aims to evaluate the effects of a 6-week dance-based multimodal exercise program on CIPN symptoms over a 3-month period, comparing outcomes with usual care in cancer patients with solid tumors.\n\nMethods: An assessor-blinded pilot randomized controlled trial with process evaluation will be conducted at Community Cancer Centers\u002F Community Centers and Non-governmental organizations. A total of 76 participants will be recruited, with both intervention and control groups receiving educational booklets and logbooks. The intervention group will engage in a 6-week dance-based multimodal exercise program, supplemented by goal-setting evaluations and motivational messaging. The control group will receive weekly exercise videos and motivational messages. Outcomes, including CIPN severity, quality of life, pain, balance, exercise knowledge, motivation, self-efficacy, and adverse effects, will be measured using validated tools at baseline, immediately post-intervention, 4 weeks post-intervention, and 12 weeks post-intervention. Process evaluation will explore perceived benefits, program awareness, and facilitators and barriers to adherence.\n\nConclusion: This study aims to provide an evidence-based approach for managing CIPN in cancer patients through a dance-based multimodal exercise program. It underscores the importance of incorporating the IMB model to enhance exercise adherence and support self-management of CIPN in cancer survivors.",[484],"Cancer",[486,487,488,489],"cancers","malignant solid tumors","chemotehrapy-induced peripheral neuropathy","CIPN","2026-06-02",{"date":413,"type":32},{"date":220,"type":21},{"date":494,"type":21},"2026-12-31",{"name":38,"class":39},{"id":497,"slug":498,"hasResults":12,"nctId":499,"briefTitle":500,"officialTitle":501,"acronym":502,"eligibilityCriteria":503,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":504,"targetDuration":4,"studyType":22,"phases":506,"briefSummary":507,"conditions":508,"keywords":514,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":520,"startDateStruct":521,"completionDateStruct":523,"leadSponsor":525,"locationsCount":526},"100627688","phase-2-adjunctive-fludrocortisone-in-septic-shock-100627688","NCT07451886","Adjunctive Fludrocortisone in Septic Shock","Adjunctive Fludrocortisone in Septic Shock: a Multicenter, Double-blind, Randomized, Placebo-controlled Pilot Trial (AFLUDROS-1)","AFLUDROS-1","Inclusion Criteria:\n\n1. suspected or confirmed adult sepsis as defined by ≥ 2 increase in Sequential Organ Failure Assessment (SOFA) score due to infection\n2. ≥0.25 μg\u002Fkg\u002Fmin of noradrenaline infusion or vasoactive-inotropic score (VIS) ≥25 to maintain mean arterial pressure (MAP) ≥65 mmHg for at least 1 hour\n3. onset of septic shock within 24 hours\n4. shock due to infection with no other proven or apparent cause\n5. hypoperfusion defined as arterial or venous lactate concentration \\>2.0 mmol\u002FL\n6. mechanical ventilation\n\nExclusion Criteria:\n\n1. fludrocortisone cannot be administered within 24 hours of onset of septic shock\n2. death is deemed imminent or inevitable by treating clinicians\n3. limitation of therapy\n4. an underlying disease process with a life expectancy of less than 90 days\n5. pregnancy (confirmed or suspected)\n6. receiving immunomodulatory agents including hydrocortisone \\> 300mg\u002Fday\n7. enteral medication cannot be administered\n8. prescribed fludrocortisone for other medical condition\n9. contraindication to hydrocortisone or fludrocortisone",{"count":505,"type":21},32,[24],"Sepsis is a life-threatening condition caused by the body's dysregulated response to an infection. While corticosteroids are known to help stabilize blood pressure in septic shock, their ability to reduce mortality is still debated. Recent analyses suggest that combining fludrocortisone with hydrocortisone may be more effective at saving lives than hydrocortisone alone.\n\nTo test this hypothesis, a large, definitive international trial is needed. However, this research proposal is for a smaller pilot study (Phase II) involving 32 critically ill patients. The primary goal of this pilot is to determine the feasibility of conducting the subsequent large-scale trial that would compare hydrocortisone alone against the combination therapy and potentially change medical practice.",[509,510,511,512,513],"Sepsis","Septic Shock","Sepsis - to Reduce Mortality in the Intensive Care Unit","Sepsis and Septic Shock","Sepsis at Intensive Care Unit",[515,516,509,517,518,519],"Fludrocortisone","Septic shock","hydrocortisone","intensive care unit","pilot",{"date":490,"type":32},{"date":522,"type":32},"2026-04-01",{"date":524,"type":21},"2028-07-31",{"name":38,"class":39},5,{"id":528,"slug":529,"hasResults":12,"nctId":530,"briefTitle":531,"officialTitle":532,"acronym":4,"eligibilityCriteria":533,"healthyVolunteers":47,"sex":17,"minAge":18,"maxAge":534,"enrollmentInfo":535,"targetDuration":4,"studyType":315,"phases":4,"briefSummary":537,"conditions":538,"keywords":541,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":543,"lastUpdatePostDateStruct":544,"startDateStruct":545,"completionDateStruct":546,"leadSponsor":547,"locationsCount":40},"100638419","perception-risk-behaviour-and-attitudes-related-to-non-communicable-disease-100638419","NCT07597434","Perception, Risk Behaviour, and Attitudes Related to Non-communicable Disease","Understanding of the Perception, Risk Behaviour, and Attitudes Related to Non-communicable Disease Among Adolescents and Young Adults: An Exploratory Study","Inclusion Criteria:\n\n* (1) Aged 18 to 45 years\n* (2) Able to speak Cantonese\n\nExclusion Criteria:\n\n* (1) Studying medical, nursing and healthcare related courses or working in medical, nursing, and allied health fields\n* (2) Those who had been diagnosed with non-communicable diseases","45 Years",{"count":536,"type":21},5000,"The study is to explore the understanding of the perception, risk behaviour, and attitudes related to non-communicable diseases among adolescents and young adults. The objectives of the study are:\n\n1. To investigate the understanding of non-communicable diseases among adolescents and young adults;\n2. To identify the prevalence of health-risk behaviours among adolescents and young adults;\n3. To examine the attitudes and behaviours to prevent non-communicable diseases among adolescents and young adults",[539,540],"Health-risk Behaviours","Non Communicable Diseases",[539,540,542],"young adults","2026-05-29",{"date":490,"type":32},{"date":543,"type":32},{"date":445,"type":21},{"name":38,"class":39},{"id":549,"slug":550,"hasResults":12,"nctId":551,"briefTitle":552,"officialTitle":553,"acronym":4,"eligibilityCriteria":554,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":555,"enrollmentInfo":556,"targetDuration":4,"studyType":22,"phases":558,"briefSummary":559,"conditions":560,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":562,"lastUpdatePostDateStruct":563,"startDateStruct":564,"completionDateStruct":566,"leadSponsor":568,"locationsCount":40},"100638418","the-efficacy-and-safety-of-female-prp-co-incubation-with-sperm-during-iui-cycles-100638418","NCT07615634","The Efficacy and Safety of Female PRP Co-incubation With Sperm During (IUI) Cycles","The Efficacy and Safety of Female Autologous Platelet-Rich Plasma (PRP) Co-incubation With Sperm During the Intrauterine Insemination (IUI) Cycles: A Prospective, Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients who were eligible for IUI cycles in Assissted Reproduction Technolog unit, Prince of Wales Hospital\n* Female patients aged \\>18 years old and \\\u003C 42 years old\n* BMI \\\u003C 30 kg\u002Fm2\n\nExclusion Criteria:\n\n* Concurrent administration of other agents such as prednisolone, intravenous immunoglobulin, or G-CSF\n* Administration of anticoagulants or NSAIDs at least 7 days before PRP infuse\n* Drug addiction\n* Untreated urinary tract infection\n* Underlying uncontrolled diabetes or hypertension, chromosomal or uterine abnormalities, genetic, hematologic, immunological, or endocrine disorders\n* Chronic disease, systemic disease or cancers\n* Blood diseases (sepsis, thrombocytopenia)\n* Poor sperm samples (raw sample TMS \\\u003C5 x 106)\n* Smoking and drinking alcoholic beverages on the day of IUI\n* Fever on the day of IUI\n* Redduse or incomplete in obtaining informed consent","42 Years",{"count":557,"type":21},288,[52],"The investigators hypothesize that infertility patients undergoing IUI who receive female autologous platelet-rich plasma (PRP) co-incubation with husband's sperm would have higher clinical pregnancy rate.\n\nPrimary outcome:\n\nTo compare the incidence of clinical pregnancy outcome in those infertility patients undergoing IUI with female PRP co-incubation with husband's sperm group and non-PRP group.\n\nSecondary outcomes:\n\n* To evaluate the post-culture sperm parameters between the intervention group and control group\n* To evaluate the IUI parameter between the intervention group and control group\n* To evaluate the safeness between the female PRP co-incubation with husband's sperm in the IUI group and non-PRP group, including potential infection rate or other pregnancy outcomes such as miscarriage, multiple pregnancy, ectopic pregnancy and molar pregnancy",[561],"Reproductive Issues","2026-05-28",{"date":543,"type":32},{"date":565,"type":21},"2026-05-21",{"date":567,"type":21},"2028-05-20",{"name":38,"class":39},{"id":570,"slug":571,"hasResults":12,"nctId":572,"briefTitle":573,"officialTitle":573,"acronym":4,"eligibilityCriteria":574,"healthyVolunteers":47,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":575,"targetDuration":4,"studyType":22,"phases":577,"briefSummary":578,"conditions":579,"keywords":585,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":592,"lastUpdatePostDateStruct":593,"startDateStruct":594,"completionDateStruct":596,"leadSponsor":598,"locationsCount":71},"100589498","youth-for-youth-mental-wellness-care-and-action-100589498","NCT06955195","Youth-for-Youth Mental Wellness Care and Action","Inclusion Criteria:\n\n* student in Hong Kong secondary school\n* Studying at Form 1 to Form 3 at the time of recruitment\n* Competence in comprehending written Chinese or English\n* Competence in speaking Cantonese or English\n* Written consent from students and their legal guardian\n\nExclusion Criteria:\n\n* Not studying at Form 1 to 3 in Hong Kong secondary school\n* Incompetence in comprehending written Chinese or English\n* Incompetence in speaking Cantonese or English\n* No written consent from students or their legal guardian",{"count":576,"type":21},18000,[52],"This initiative aims to improve flourishing and quality of life of secondary school students, reduce mental distress (e.g., depression and suicidal ideation), enhance their understanding of mental health (e.g., mental health literacy) and help-seeking intention, and foster a supportive school environment (e.g., school climate-caring relationship, and sense of community). Also, this initiative aims to improve students' process of change in psychological (e.g., mattering, emotion regulation, empowerment) and social (e.g., trust belief) aspects and mental health awareness (e.g., mental health stigma). The feasibility, acceptability, and sustainability of the programme from multiple perspectives (e.g., students, student leaders, and stakeholders) will also be evaluated. In addition, the cost-effectiveness of delivering this programme (e.g., the incremental cost-effectiveness ratio (ICER)) among secondary schools in Hong Kong will be assessed.\n\nThe programme will be implemented among students in 130 local secondary schools over three academic years. The first is a pilot phase (Year 1), which 40 schools will implement the intervention and student participants will be evaluated at pre- (T0) and post-intervention (T1) using questionnaires. In this stage, participatory research will be conducted before and after the intervention among students, student leaders, and stakeholders in 20 pilot schools to co-design the intervention, ensuring the programme meet the actual wellness needs of youth. In following two academic years, an additional 90 schools will participate in a cluster randomized controlled trial (RCT) with a 1:1 ratio between intervention and waitlist control groups. Each year, 45 schools will implement the intervention. Summative evaluation will be conducted among RCT schools at T0 and T1, and 3-month follow-up (T2). Quantitative data be collected to assess the effectiveness of intervention, and qualitative data will provide understanding of students' and stakeholders' perspectives of the intervention implementation. Cost outcomes will include intervention costs and cost savings, calculated from the payer (i.e., JC\u002Fgovernment) perspective using administrative records or validated tools. The primary outcome of cost-effectiveness will be the quality-adjusted life-years (QALYs) of students. Cost of implementing the intervention program and QALYs will be used to evaluate the cost-effectiveness of the intervention, for example, estimate the incremental cost-effectiveness ratio (ICER).",[580,581,582,583,584],"Mental Well-being","Adolescent Health","Mental Health Literacy","School Difficulties Associated With Mental Health Problems","Mental Health Help-Seeking",[586,587,588,589,590,591],"MENTAL HEALTH","ADOLESCENT MENTAL HEALTH","SCHOOL CLIMATE ON MENTAL HEALTH","MENTAL HEALTH FRIENDLY CAMPUS","MENTAL HELP-SEEKING BEHAVIOR","MENTAL HEALTH LITERACY","2026-05-27",{"date":543,"type":32},{"date":595,"type":32},"2025-08-21",{"date":597,"type":21},"2027-12-31",{"name":38,"class":39},{"id":600,"slug":601,"hasResults":12,"nctId":602,"briefTitle":603,"officialTitle":603,"acronym":604,"eligibilityCriteria":605,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":606,"enrollmentInfo":607,"targetDuration":4,"studyType":22,"phases":608,"briefSummary":609,"conditions":610,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":612,"lastUpdatePostDateStruct":613,"startDateStruct":614,"completionDateStruct":616,"leadSponsor":617,"locationsCount":224},"100638500","phase-2-glp-1-receptor-agonist-in-primary-intracerebral-hemorrhage-a-phase-2-randomized-trial-100638500","NCT07613437","GLP-1 Receptor Agonist in Primary Intracerebral Hemorrhage: A Phase 2 Randomized Trial","GLICH","Inclusion Criteria:\n\n* 1\\. Primary spontaneous ICH with hematoma location in putamen (10-30mL) or thalamus (5-15mL) on admission CT imaging. Both locations are selected because they are strongly associated with hypertensive arteriopathy-related ICH and there is limited evidence supporting neurosurgical intervention compared with posterior fossa hemorrhages. The thalamic and putaminal volume cutoffs are based on a recent observational study showing that restricting enrolment to 5-15 mL (thalamus) and 10-30 mL (putamen) enriches for patients with substantial but potentially modifiable prognosis while avoiding extremes with ceiling or floor effects. For patients with hematoma involving both putamen and thalamus, a volume cutoff of 5-30mL will be used.\n* 2\\. National Institutes of Health Stroke Scale (NIHSS) score ≥ 6 AND ≤ 25 at presentation\n* 3\\. Glasgow Coma Scale (GCS) score ≥ 10\n* 4\\. Last-known-well (LKW) to presentation time ≤ 24 hours\n* 5\\. Pre-stroke modified Rankin Scale (mRS) ≤ 2\n* 6\\. Patients deemed not suitable for acute neurosurgical intervention at the time of randomization\n* 7\\. Informed consent obtained from patient (if mentally competent) or legal representative, as per national laws, regulations, and applicable ethics committee requirements\n\nExclusion Criteria:\n\n* 1\\. Secondary ICH: ICH due to macrovascular abnormalities (e.g., arteriovenous malformation, aneurysm, arterial dissection, cavernous malformation), coagulopathy, anticoagulant use, antiplatelet overdose, or thrombocytopenia.\n* 2\\. ICH involving locations other than putamen or thalamus (e.g., lobar, brainstem, cerebellar, isolated intraventricular hemorrhage). Extension of hematoma into other structures is allowed if the hematoma centroid is within the thalamus or putamen, and the hematoma volume does not exist the respective thresholds as stated in Inclusion Criterion 1.\n* 3\\. ICH with planned neurosurgical procedure prior to randomization, including hematoma evacuation, external ventricular drainage and decompressive craniectomy.\n* 4\\. Estimated or known body mass index (BMI) \\\u003C 18 kg\u002Fm².\n* 5\\. Pregnancy, lactation, or positive urine or serum beta human chorionic gonadotropin (β-hCG) test. β-hCG testing should be guided by clinical need.\n* 6\\. Creatinine clearance \\\u003C 30 mL\u002Fmin (estimated by Cockcroft-Gault equation or measured)\n* 7\\. Severe or fatal comorbid illness with life expectancy \\\u003C 3 years (e.g., terminal malignancy, advanced organ failure)\n* 8\\. Participation in another clinical trial investigating a drug, medical device, or medical procedure within 30 days preceding trial inclusion.\n* 9\\. Known history of allergy or hypersensitivity to GLP-1RA.\n* 10\\. Family or personal history of multiple endocrine neoplasia (MEN), medullary thyroid carcinoma, or pancreatic carcinoma\n* 11\\. Active sepsis at time of randomization, defined as a body temperature of ≥ 38.5C, or suspected or documented infection and acute organ dysfunction, operationalized as an increase in SOFA score ≥ 2 points from baseline (baseline assumed 0 if no pre-existing organ dysfunction)\n* 12\\. Contraindications to proposed imaging studies (e.g., pacemaker incompatibility with MRI where applicable)","100 Years",{"count":180,"type":21},[24],"Intracerebral hemorrhage (ICH) is a devastating form of acute stroke with poor clinical outcomes. Although ICH accounted only for 28.8% of incident strokes, it was responsible for nearly half of the long-term burden of stroke measured in disability-adjusted life years . In contrast to the improving outcomes seen in ischemic stroke with advances in reperfusion therapy, outcomes of patients with ICH have shown little progress over the past two decades. Current standard care focuses primarily on blood pressure control and supportive management, yet rate of functional independence remained modest. Randomized evidence suggested that fewer than half of the ICH patients achieved independent activities of daily living even with intensive blood pressure lowering.\n\nA cascade of pathophysiological events is thought to determine the prognosis of ICH. First, the mass effect of the hematoma and its expansion with uncontrolled blood pressure cause primary neuronal injury. Second, neuroinflammation involving blood-brain barrier (BBB) dysfunction, activated microglia and astrocytes, together with neutrophil infiltration in response to extravascular blood, propagates neuronal injury, leading to perihematomal edema. Third, the direct neurotoxicity of blood breakdown products and oxidative stress may further amplify neuroinflammation. Mitigating hematoma expansion through intensive blood pressure control therefore only addresses one of these three pathophysiological processes, and is constrained by a short treatment window, mostly within 6 hours. Therapeutic strategies targeting secondary neuroinflammation should therefore be actively pursued. In addition, multimodal studies incorporating longitudinal imaging and omics markers are needed to elucidate the key pathways mediating neuroinflammation following ICH.\n\nRecent preclinical evidence suggests that glucagon-like peptide-1 receptor agonists (GLP-1RA) may offer neuroprotective benefits in ICH. In animal models of ICH, intracerebroventricular liraglutide suppressed neuroinflammation, prevented brain edema, and reduced neurologic deficits. Previous work from our group has also shown that, across several animal models, GLP-1RA attenuates BBB dysfunction and suppresses neuroinflammatory signaling via microglial modulation. Importantly, a recent translational clinical trial by our team has also provided preliminary evidence that GLP-1RA exerts neuroprotective effects in patients with large vessel occlusion strokes. We therefore hypothesize that compared to standard therapy, administration of GLP-1RA in patients with primary ICH may limit perihaematomal edema, reduce secondary brain injury, and improve neurological outcomes.\n\nIn this phase 2, randomized, open-label pilot study with blinded endpoint assessment, we aim to determine the safety and signals for efficacy of GLP-1RA in patients with primary ICH.",[611],"Intracerebral Hemorrhage","2026-05-22",{"date":543,"type":32},{"date":615,"type":21},"2026-06-15",{"date":417,"type":21},{"name":38,"class":39},""]